{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:17Z","timestamp":1791908297660,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.neurol.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T09:45:02Z","timestamp":1626860702000},"page":"980-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society"],"prefix":"10.1016","volume":"177","author":[{"given":"C.","family":"Papeix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Donze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebrun-Fr\u00e9nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Donz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebrun-Fr\u00e9nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Thouvenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pourcher-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cara-Dalliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Guen-noc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Casez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maarouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Louapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Androdias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mattey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bernady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Faucheux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Meckies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tourniaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Guennoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Durnad-Dubief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wiertlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Derache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Le page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pittion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Clavelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Heinzlef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Colamarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Planque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sheiber nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alchaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bensmail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Castan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Creange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Creisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"DeBroucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Depaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Douay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dulau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grimaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lanotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Magy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maurousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Montcuquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Patry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peaureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saint-Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Taithe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vuoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0505","doi-asserted-by":"crossref","first-page":"e61110","DOI":"10.1371\/journal.pone.0061110","article-title":"Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis","volume":"8","author":"Almohmeed","year":"2013","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.neurol.2021.04.011_bib0510","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.neurol.2021.04.011_bib0515","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/rmv.503","article-title":"Multiple sclerosis is linked to Epstein-Barr virus infection","volume":"16","author":"Haahr","year":"2006","journal-title":"Rev Med Virol"},{"issue":"9.","key":"10.1016\/j.neurol.2021.04.011_bib0520","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neurol.2021.04.011_bib0525","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1352458512449682","article-title":"The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis","volume":"19","author":"Pakpoor","year":"2013","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.neurol.2021.04.011_bib0530","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S0950268801005891","article-title":"Multiple sclerosis and varicella zoster virus infection: a review","volume":"127","author":"Marrie","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0535","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1191\/1352458506ms1291oa","article-title":"Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis","volume":"12","author":"Bagos","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.04.011_bib0540","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jneuroim.2018.06.011","article-title":"Is Toxoplasma gondii playing a positive role in multiple sclerosis risk?. A systematic review and meta-analysis","volume":"322","author":"Saberi","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0545","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.msard.2016.03.013","article-title":"Association between Helicobacter pylori infection and multiple sclerosis: a systematic review and meta-analysis","volume":"7","author":"Jaruvongvanich","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"Pt 5","key":"10.1016\/j.neurol.2021.04.011_bib0550","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/brain\/awf098","article-title":"Prospective study on the relationship between infections and multiple sclerosis exacerbations","volume":"125","author":"Buljevac","year":"2002","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.neurol.2021.04.011_bib0555","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00867354","article-title":"Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study","volume":"240","author":"Andersen","year":"1993","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0560","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.wnl.0000233834.09743.3b","article-title":"The risk of relapses in multiple sclerosis during systemic infections","volume":"67","author":"Correale","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.04.011_bib0565","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/jnnp.64.6.736","article-title":"Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis","volume":"64","author":"Edwards","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"S1","key":"10.1016\/j.neurol.2021.04.011_bib0570","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/ana.410360709","article-title":"Influence of infection on exacerbations of multiple sclerosis","volume":"36","author":"Panitch","year":"1994","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0575","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000166602","article-title":"Monthly ambient sunlight, infections and relapse rates in multiple sclerosis","volume":"31","author":"Tremlett","year":"2008","journal-title":"Neuroepidemiology"},{"issue":"6","key":"10.1016\/j.neurol.2021.04.011_bib0580","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/1352458510394397","article-title":"Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence","volume":"17","author":"Oikonen","year":"2011","journal-title":"Mult Scler"},{"issue":"8441","key":"10.1016\/j.neurol.2021.04.011_bib0585","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(85)92801-6","article-title":"Clinical viral infections and multiple sclerosis","volume":"1","author":"Sibley","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neurol.2021.04.011_bib0590","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neurol.2019.04.001","article-title":"French Group for recommendations in multiple sclerosis France4MS the Soci\u00e9t\u00e9 francophone de la scl\u00e9rose en plaques SFSEP, List of investigators. Immunization and multiple sclerosis: recommendations from the French Multiple Sclerosis Society","volume":"175","author":"Lebrun","year":"2019","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0595","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1352458507084650","article-title":"Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study","volume":"14","author":"Leone","year":"2008","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.neurol.2021.04.011_bib0600","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","article-title":"Hospital admission due to infections in multiple sclerosis patients","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0605","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp-2015-310361","article-title":"Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios","volume":"87","author":"Manouchehrinia","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.neurol.2021.04.011_bib0610","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.neurol.2020.02.011","article-title":"Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society","volume":"176","author":"Donz\u00e9","year":"2020","journal-title":"Rev Neurol (Paris)"},{"issue":"10","key":"10.1016\/j.neurol.2021.04.011_bib0615","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0000000000000753","article-title":"Dramatically changing rates and reasons for hospitalization in multiple sclerosis","volume":"83","author":"Marrie","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurol.2021.04.011_bib0620","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","article-title":"Epidemiology of multiple sclerosis: results from a large observational study in the UK","volume":"262","author":"Jick","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0625","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients WIth Coronavirus Disease 2019 and Multiple Sclerosis","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0630","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study group","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2021.04.011_bib0635","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial","volume":"45","author":"The I.F.N.B Multiple Sclerosis Study group","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0640","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"9139","key":"10.1016\/j.neurol.2021.04.011_bib0645","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","author":"PRISMS study Goup","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.neurol.2021.04.011_bib0650","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2021.04.011_bib0655","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0660","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurol.2021.04.011_bib0665","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neurol.2018.03.012","article-title":"First-line therapy in relapsing remitting multiple sclerosis","volume":"174","author":"Biotti","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.04.011_bib0670","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ane.12712","article-title":"Safety concerns and risk management of multiple sclerosis therapies","volume":"136","author":"Soelberg Sorensen","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2021.04.011_bib0675","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0680","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study group","volume":"6","author":"Johnson","year":"2000","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0685","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1191\/135248506ms1318oa","article-title":"A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients","volume":"12","author":"Ford","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.04.011_bib0690","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/14737175.2019.1627201","article-title":"Assessing the risk of multiple sclerosis disease-modifying therapies","volume":"19","author":"Ayrignac","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"10.1016\/j.neurol.2021.04.011_bib0695","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0700","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0705","first-page":"11","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","author":"O\u2019Connor","year":"2011","journal-title":"New Eng J Med"},{"key":"10.1016\/j.neurol.2021.04.011_bib0710","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2021.04.011_bib0715","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.neurol.2021.04.011_bib0720","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1212\/WNL.0000000000004804","article-title":"PML in a person with multiple sclerosis: Is teriflunomide the felon?","volume":"90","author":"Lorefice","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurol.2021.04.011_bib0725","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-Controlled Phase 3 Study of Oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurol.2021.04.011_bib0730","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 Study of Oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurol.2021.04.011_bib0735","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.neurol.2021.04.011_bib0740","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s12325-018-0788-8","article-title":"72-week safety and tolerability of dimethyl fumarate in japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled. Phase III APEX study and its open-label extension","volume":"35","author":"Ochi","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurol.2021.04.011_bib0745","article-title":"Expanding spectrum of opportunistic infections associated with dimethyl fumarate","author":"Kim","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2021.04.011_bib0750","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","author":"Jordan","year":"2020","journal-title":"Mult Scler"},{"issue":"10127","key":"10.1016\/j.neurol.2021.04.011_bib0755","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2021.04.011_bib0760","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0765","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurol.2021.04.011_bib0770","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.neurol.2021.04.011_bib0775","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10072-016-2701-z","article-title":"Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy","volume":"38","author":"Laroni","year":"2017","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0780","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"10.1016\/j.neurol.2021.04.011_bib0785","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.04.011_bib0790","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2021.04.011_bib0795","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.msard.2017.05.004","article-title":"Cerebral toxoplasmosis in an MS patient receiving Fingolimod","volume":"18","author":"Enriquez-Marulanda","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2021.04.011_bib0800","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7224\/1537-2073.2018-080","article-title":"Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease","volume":"21","author":"Samudralwar","year":"2019","journal-title":"Int J MS Care"},{"issue":"1","key":"10.1016\/j.neurol.2021.04.011_bib0805","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2020.01.233","article-title":"L\u00e9sions \u00e0 Human Papilloma Virus (HPV) sous fingolimod: une s\u00e9rie de 14 cas [online","author":"Mhanna","year":"2020","journal-title":"Rev Neurol (Paris) Rev Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0815","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1177\/1352458518807088","article-title":"Warts and all: Fingolimod and unusual HPV-associated lesions","volume":"25","author":"Triplett","year":"2019","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"11","key":"10.1016\/j.neurol.2021.04.011_bib0820","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458518813109","article-title":"Clinical commentary on \u201cWarts and all: Fingolimod and unusual HPV associated lesions\u201d","volume":"25","author":"Macaron","year":"2019","journal-title":"Mult Scler."},{"issue":"5","key":"10.1016\/j.neurol.2021.04.011_bib0825","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: The ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.neurol.2021.04.011_bib0830","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0835","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0840","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","author":"Giovannoni","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurol.2021.04.011_bib0845","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0850","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0855","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9350","key":"10.1016\/j.neurol.2021.04.011_bib0860","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.neurol.2021.04.011_bib0865","first-page":"CD002127","article-title":"Mitoxantrone for multiple sclerosis","author":"Martinelli Boneschi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.neurol.2021.04.011_bib0870","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurol.2021.04.011_bib0875","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurol.2021.04.011_bib0880","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"issue":"88.","key":"10.1016\/j.neurol.2021.04.011_bib0885","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"20","key":"10.1016\/j.neurol.2021.04.011_bib0890","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurol.2021.04.011_bib0895","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2021.04.011_bib0900","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2014.03.007","article-title":"Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab","volume":"340","author":"Valenzuela","year":"2014","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.neurol.2021.04.011_bib0905","doi-asserted-by":"crossref","first-page":"ofw038","DOI":"10.1093\/ofid\/ofw038","article-title":"Acute Cryptococcal immune reconstitution inflammatory syndrome in a patient on natalizumab","volume":"3","author":"Gundacker","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.neurol.2021.04.011_bib0910","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients","volume":"57","author":"Fine","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.neurol.2021.04.011_bib0915","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s13760-019-01131-5","article-title":"Cerebral abscess in a multiple sclerosis patient during treatment with natalizumab","volume":"120","author":"Durmus","year":"2020","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0920","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0925","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"9805","key":"10.1016\/j.neurol.2021.04.011_bib0930","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.neurol.2021.04.011_bib0935","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2021.04.011_bib0940","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.neurol.2021.04.011_bib0945","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.04.011_bib0950","article-title":"Experience with long-term rituximab use in a multiple sclerosis clinic","volume":"2","author":"Barra","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0955","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2021.04.011_bib0960","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2021.04.011_bib0965","doi-asserted-by":"crossref","first-page":"ofy356","DOI":"10.1093\/ofid\/ofy356","article-title":"Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis","volume":"6","author":"Ciardi","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.neurol.2021.04.011_bib0970","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4254\/wjh.v7.i3.344","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs","volume":"7","author":"Nard","year":"2015","journal-title":"WJH"},{"issue":"9","key":"10.1016\/j.neurol.2021.04.011_bib0975","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0980","first-page":"218","article-title":"\u00c9pid\u00e9miologie de la rougeole en France en 2011-2018","volume":"13","author":"Antona","year":"2019","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"10.1016\/j.neurol.2021.04.011_bib0985","article-title":"Human papillomavirus infections in patients with relapsing remitting multiple sclerosis treated with fingolimod","author":"Mhanna","year":"2020","journal-title":"EAN Oral Communication"},{"key":"10.1016\/j.neurol.2021.04.011_bib0990","article-title":"Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France","author":"Vukusic","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2021.04.011_bib0995","doi-asserted-by":"crossref","first-page":"106142","DOI":"10.1016\/j.clineuro.2020.106142","article-title":"Ocrelizumab treatment in patients with primary progressive multiple sclerosis: short-term safety results from a compassionate use programme in germany","volume":"197","author":"Rauer","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.neurol.2021.04.011_bib1000","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, Journal of Neurology","volume":"62","author":"Edan","year":"1997","journal-title":"Neurosurg Psychiatry"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721006020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721006020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:44:15Z","timestamp":1758519855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378721006020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0035378721006020"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.04.011","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}